Loading...

We've got a brand new version of Simply Wall St! Try it out

Rubicon Organics

CNSX:ROMJ
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ROMJ
CNSX
CA$89M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Rubicon Organics Inc. produces and sells cannabis in Canada. The last earnings update was 27 days ago. More info.


Add to Portfolio Compare Print
  • Rubicon Organics has significant price volatility in the past 3 months.
ROMJ Share Price and Events
7 Day Returns
-1.8%
CNSX:ROMJ
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
-
CNSX:ROMJ
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
ROMJ Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Rubicon Organics (ROMJ) -1.8% 2.3% -24.9% - - -
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • No trading data on ROMJ.
  • No trading data on ROMJ.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Rubicon Organics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Rubicon Organics. This is due to cash flow or dividend data being unavailable. The share price is CA$2.23.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Rubicon Organics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Rubicon Organics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:ROMJ PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in CAD CA$-0.43
CNSX:ROMJ Share Price ** CNSX (2019-09-20) in CAD CA$2.23
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Rubicon Organics.

CNSX:ROMJ PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:ROMJ Share Price ÷ EPS (both in CAD)

= 2.23 ÷ -0.43

-5.22x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Rubicon Organics is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Rubicon Organics is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Rubicon Organics's expected growth come at a high price?
Raw Data
CNSX:ROMJ PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.22x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Rubicon Organics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Rubicon Organics's assets?
Raw Data
CNSX:ROMJ PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in CAD CA$0.49
CNSX:ROMJ Share Price * CNSX (2019-09-20) in CAD CA$2.23
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:ROMJ PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:ROMJ Share Price ÷ Book Value per Share (both in CAD)

= 2.23 ÷ 0.49

4.52x

* Primary Listing of Rubicon Organics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Rubicon Organics is overvalued based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Rubicon Organics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Rubicon Organics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Rubicon Organics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Rubicon Organics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
97.7%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Rubicon Organics expected to grow at an attractive rate?
  • Unable to compare Rubicon Organics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Rubicon Organics's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Rubicon Organics's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:ROMJ Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:ROMJ Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:ROMJ Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-06-30 1 -11 -15
2019-03-31 2 -7 -30
2018-12-31 2 -9 -30
2018-09-30 2 -10 -26
2018-06-30 1 -5 -23
2018-03-31 1 -7 -8
2017-12-31 1 -4 -6
2016-12-31 2 0 2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Rubicon Organics is high growth as no earnings estimate data is available.
  • Unable to determine if Rubicon Organics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:ROMJ Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Rubicon Organics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:ROMJ Past Financials Data
Date (Data in CAD Millions) EPS *
2019-06-30 -0.43
2019-03-31 -0.86
2018-12-31 -0.89
2018-09-30 -0.80
2018-06-30 -0.82
2018-03-31 -1.74
2017-12-31 -0.21
2016-12-31 0.52

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Rubicon Organics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of ROMJ’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Rubicon Organics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Rubicon Organics's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Rubicon Organics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Rubicon Organics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Rubicon Organics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Rubicon Organics's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Rubicon Organics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Rubicon Organics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Rubicon Organics's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Rubicon Organics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Rubicon Organics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:ROMJ Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 1.19 -15.29 13.95
2019-03-31 1.65 -29.77 12.50
2018-12-31 2.03 -29.88 12.02
2018-09-30 1.85 -25.60 8.40
2018-06-30 1.34 -23.32 6.38
2018-03-31 1.26 -8.23 7.32
2017-12-31 0.88 -5.85 5.18
2016-12-31 2.48 2.47 0.01

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Rubicon Organics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Rubicon Organics has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Rubicon Organics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Rubicon Organics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Rubicon Organics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Rubicon Organics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Rubicon Organics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Rubicon Organics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Rubicon Organics's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Rubicon Organics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Rubicon Organics Company Filings, last reported 2 months ago.

CNSX:ROMJ Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 18.14 12.55 2.48
2019-03-31 20.48 6.57 1.59
2018-12-31 22.06 3.28 0.23
2018-09-30 24.79 3.13 2.54
2018-06-30 20.39 4.27 3.96
2018-03-31 14.45 0.21 0.00
2017-12-31 16.69 3.14 2.92
2016-12-31 9.30 1.77 1.57
  • Rubicon Organics's level of debt (69.2%) compared to net worth is high (greater than 40%).
  • Unable to establish if Rubicon Organics's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Rubicon Organics has less than a year of cash runway based on current free cash flow.
  • Rubicon Organics has less than a year of cash runway if free cash flow continues to grow at historical rates of 57.4% each year.
X
Financial health checks
We assess Rubicon Organics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Rubicon Organics has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Rubicon Organics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Rubicon Organics dividends.
If you bought CA$2,000 of Rubicon Organics shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Rubicon Organics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Rubicon Organics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:ROMJ Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Rubicon Organics has not reported any payouts.
  • Unable to verify if Rubicon Organics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Rubicon Organics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Rubicon Organics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Rubicon Organics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Rubicon Organics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Rubicon Organics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Rubicon Organics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jesse McConnell
COMPENSATION CA$197,609
TENURE AS CEO 4.3 years
CEO Bio

Mr. Jesse McConnell, M.A is Co-Founder of Rubicon Organics, Inc. and serves as its Chief Executive Officer and Director. Mr. McConnell, M.A. is a Co-Founder of Whistler Medical Marijuana Corp. and an expert in organic cannabis cultivation. Mr. McConnell was instrumental in establishing the first federally legal, certified organic cannabis cultivation facility in the World. He has extensive knowledge of organic, scientific, technical, regulatory, and quality-related best practices governing medical cannabis and Certified Organic growing methods. He served as Member of Advisory Board at Veritas Pharma Inc., since February 10, 2016 until December 2018. He holds a Master's degree in Philosophy from the University of Victoria.

CEO Compensation
  • Insufficient data for Jesse to compare compensation growth.
  • Jesse's remuneration is about average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the Rubicon Organics management team in years:

2.8
Average Tenure
  • The tenure for the Rubicon Organics management team is about average.
Management Team

Jesse McConnell

TITLE
Co-Founder
COMPENSATION
CA$198K
TENURE
4.3 yrs

Margaret Brodie

TITLE
CFO & Director
COMPENSATION
CA$183K
AGE
41
TENURE
2.8 yrs

Peter Doig

TITLE
Chief Scientific Officer
COMPENSATION
CA$181K
AGE
41
TENURE
1.3 yrs

Melanie Ramsey

TITLE
Vice President of Marketing & Innovation

Tim Roberts

TITLE
President of North America
Board of Directors Tenure

Average tenure and age of the Rubicon Organics board of directors in years:

1.3
Average Tenure
61
Average Age
  • The average tenure for the Rubicon Organics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Jesse McConnell

TITLE
Co-Founder
COMPENSATION
CA$198K
TENURE
4.3 yrs

Margaret Brodie

TITLE
CFO & Director
COMPENSATION
CA$183K
AGE
41
TENURE
1.3 yrs

John Disher

TITLE
Independent Director
AGE
61
TENURE
0.4 yrs

David Donnan

TITLE
Independent Director
AGE
64
TENURE
0.4 yrs

Eric Savics

TITLE
Independent Director

John Pigott

TITLE
Independent Director
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Rubicon Organics individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
19. Sep 19 Buy Jesse McConnell Individual 19. Sep 19 19. Sep 19 5,000 CA$2.24 CA$11,200
17. Sep 19 Buy Jesse McConnell Individual 16. Sep 19 16. Sep 19 2,600 CA$2.20 CA$5,720
13. Mar 19 Sell Eric Savics Individual 13. Mar 19 13. Mar 19 -50,000 CA$2.67 CA$-133,389
15. Jan 19 Sell Eric Savics Individual 15. Jan 19 15. Jan 19 -438,334 CA$2.26 CA$-988,443
10. Sep 19 Buy Eric Savics Individual 09. Sep 19 09. Sep 19 10,000 CA$2.15 CA$21,500
06. Sep 19 Buy Jesse McConnell Individual 03. Sep 19 05. Sep 19 6,700 CA$2.20 CA$14,518
29. Aug 19 Buy John Disher Individual 23. Aug 19 23. Aug 19 18,500 CA$2.70 CA$49,950
28. Aug 19 Buy Jesse McConnell Individual 23. Aug 19 23. Aug 19 100,000 CA$2.70 CA$270,000
26. Aug 19 Buy Margaret Brodie Individual 23. Aug 19 23. Aug 19 18,500 CA$2.70 CA$49,950
23. Aug 19 Buy Eric Savics Individual 23. Aug 19 23. Aug 19 100,000 CA$2.70 CA$270,000
20. Aug 19 Buy Eric Savics Individual 20. Aug 19 20. Aug 19 5,000 CA$2.40 CA$12,000
15. Aug 19 Buy Eric Savics Individual 15. Aug 19 15. Aug 19 5,000 CA$2.45 CA$12,250
12. Aug 19 Buy Eric Savics Individual 12. Aug 19 12. Aug 19 4,700 CA$2.58 CA$12,126
09. Aug 19 Buy Eric Savics Individual 08. Aug 19 09. Aug 19 15,000 CA$2.66 CA$39,324
06. Aug 19 Buy Eric Savics Individual 06. Aug 19 06. Aug 19 3,900 CA$3.00 CA$11,700
31. Jul 19 Buy Eric Savics Individual 31. Jul 19 31. Jul 19 10,000 CA$3.00 CA$30,000
29. Jul 19 Buy Eric Savics Individual 26. Jul 19 29. Jul 19 16,000 CA$3.00 CA$47,941
16. Jul 19 Buy Jesse McConnell Individual 15. Jul 19 15. Jul 19 500 CA$3.01 CA$1,505
16. Jul 19 Buy Eric Savics Individual 16. Jul 19 16. Jul 19 10,000 CA$3.00 CA$30,000
04. Jul 19 Buy Jesse McConnell Individual 21. Jun 19 28. Jun 19 7,700 CA$3.11 CA$23,273
19. Jun 19 Buy Jesse McConnell Individual 18. Jun 19 19. Jun 19 4,500 CA$3.30 CA$14,818
13. Jun 19 Buy Jesse McConnell Individual 06. Jun 19 12. Jun 19 16,100 CA$3.12 CA$48,964
12. Jun 19 Buy Eric Savics Individual 12. Jun 19 12. Jun 19 23,800 CA$3.00 CA$71,400
07. Jun 19 Buy Eric Savics Individual 07. Jun 19 07. Jun 19 25,000 CA$3.00 CA$75,000
06. Jun 19 Buy Jesse McConnell Individual 04. Jun 19 05. Jun 19 20,500 CA$3.15 CA$63,256
05. Jun 19 Buy Eric Savics Individual 03. Jun 19 03. Jun 19 5,500 CA$2.90 CA$15,950
03. Jun 19 Buy Jesse McConnell Individual 29. May 19 31. May 19 19,000 CA$3.10 CA$57,412
03. Jun 19 Buy Eric Savics Individual 31. May 19 31. May 19 14,200 CA$2.92 CA$41,494
29. May 19 Buy Eric Savics Individual 29. May 19 29. May 19 25,000 CA$3.04 CA$76,000
27. May 19 Buy Eric Savics Individual 27. May 19 27. May 19 13,800 CA$3.00 CA$41,400
24. May 19 Buy Eric Savics Individual 24. May 19 24. May 19 25,400 CA$3.00 CA$76,175
23. May 19 Buy Eric Savics Individual 23. May 19 23. May 19 10,000 CA$2.95 CA$29,500
21. May 19 Buy Eric Savics Individual 21. May 19 21. May 19 23,400 CA$2.91 CA$68,115
13. May 19 Buy Eric Savics Individual 10. May 19 10. May 19 30,000 CA$2.95 CA$88,500
03. May 19 Buy Eric Savics Individual 03. May 19 03. May 19 12,100 CA$2.95 CA$35,695
29. Apr 19 Buy Eric Savics Individual 24. Apr 19 26. Apr 19 7,900 CA$3.00 CA$23,614
18. Apr 19 Buy Eric Savics Individual 18. Apr 19 18. Apr 19 16,700 CA$2.90 CA$48,430
15. Apr 19 Buy Eric Savics Individual 15. Apr 19 15. Apr 19 50,000 CA$3.00 CA$150,000
01. Apr 19 Buy Eric Savics Individual 01. Apr 19 01. Apr 19 1,100 CA$3.00 CA$3,300
20. Feb 19 Buy Eric Savics Individual 19. Feb 19 19. Feb 19 8,900 CA$2.70 CA$24,030
04. Feb 19 Buy Eric Savics Individual 04. Feb 19 04. Feb 19 50,000 CA$2.75 CA$137,500
29. Jan 19 Buy Eric Savics Individual 29. Jan 19 29. Jan 19 100,000 CA$2.00 CA$200,000
27. Dec 18 Buy Eric Savics Individual 27. Dec 18 27. Dec 18 30,700 CA$1.60 CA$49,120
19. Dec 18 Buy Margaret Brodie Individual 18. Dec 18 19. Dec 18 2,900 CA$1.75 CA$4,974
19. Dec 18 Buy Eric Savics Individual 19. Dec 18 19. Dec 18 25,000 CA$1.65 CA$41,250
18. Dec 18 Buy Eric Savics Individual 18. Dec 18 18. Dec 18 25,000 CA$1.67 CA$41,688
14. Dec 18 Buy Eric Savics Individual 14. Dec 18 14. Dec 18 3,900 CA$1.80 CA$7,020
14. Dec 18 Buy Eric Savics Individual 13. Dec 18 13. Dec 18 100 CA$1.80 CA$180
07. Dec 18 Buy Jesse McConnell Individual 04. Dec 18 07. Dec 18 7,500 CA$2.03 CA$14,589
06. Dec 18 Buy Margaret Brodie Individual 06. Dec 18 06. Dec 18 5,000 CA$1.95 CA$9,750
06. Dec 18 Buy Eric Savics Individual 06. Dec 18 06. Dec 18 4,900 CA$1.90 CA$9,310
05. Dec 18 Buy Eric Savics Individual 05. Dec 18 05. Dec 18 4,600 CA$2.00 CA$9,200
04. Dec 18 Buy Eric Savics Individual 04. Dec 18 04. Dec 18 19,400 CA$2.00 CA$38,800
15. Oct 18 Buy Eric Savics Individual 10. Oct 18 12. Oct 18 60,000 CA$3.91 CA$222,061
11. Oct 18 Buy Jesse McConnell Individual 11. Oct 18 11. Oct 18 7,500 CA$3.29 CA$24,683
10. Oct 18 Buy Jesse McConnell Individual 10. Oct 18 10. Oct 18 8,150 CA$3.25 CA$26,463
10. Oct 18 Buy Margaret Brodie Individual 10. Oct 18 10. Oct 18 8,000 CA$3.42 CA$25,572
X
Management checks
We assess Rubicon Organics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Rubicon Organics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Independent Director Eric Savics Just Bought Shares In Rubicon Organics Inc. (CNSX:ROMJ)

View our latest analysis for Rubicon Organics Rubicon Organics Insider Transactions Over The Last Year Notably, that recent purchase by Eric Savics is the biggest insider purchase of Rubicon Organics shares that we've seen in the last year. … While Rubicon Organics insiders bought shares last year, they didn't sell. … When combined with notable insider ownership, these factors suggest Rubicon Organics insiders are well aligned, and that they may think the share price is too low.

Simply Wall St -

Rubicon Organics (CNSX:ROMJ) May Be Weighed Down By Its Debt

CNSX:ROMJ Historical Debt, July 26th 2019 A Look At Rubicon Organics's Liabilities We can see from the most recent balance sheet that Rubicon Organics had liabilities of CA$4.91m falling due within a year, and liabilities of CA$4.80m due beyond that. … When we look at that and recall the liabilities on its balance sheet, relative to cash, it seems unwise to us for the company to have any debt. … If, after all that, you're more interested in a fast growing company with a rock-solid balance sheet, then check out our list of net cash growth stocks without delay.

Simply Wall St -

What Kind Of Investor Owns Most Of Rubicon Organics Inc. (CNSX:ROMJ)?

Generally speaking, as a company grows, institutions will increase their ownership. … Rubicon Organics is not a large company by global standards. … Taking a look at our data on the ownership groups (below), it's seems that.

Simply Wall St -

Should You Take Comfort From Insider Transactions At Rubicon Organics Inc. (CNSX:ROMJ)?

So shareholders might well want to know whether insiders have been buying or selling shares in Rubicon Organics Inc. … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … The Last 12 Months Of Insider Transactions At Rubicon Organics.

Simply Wall St -

What You Must Know About Rubicon Organics Inc's (CNSX:ROMJ) Financial Strength

While small-cap stocks, such as Rubicon Organics Inc (CNSX:ROMJ) with its market cap of CA$66m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn.

Simply Wall St -

Company Info

Description

Rubicon Organics Inc. produces and sells cannabis in Canada. The company also leases custom built facilities; and provides brand licensing to cannabis producers and processors in Washington and California. Rubicon Organics Inc. was founded in 2015 and is headquartered in Vancouver, Canada.

Details
Name: Rubicon Organics Inc.
ROMJ
Exchange: CNSX
Founded: 2015
CA$89,125,127
39,966,425
Website: http://www.rubiconorganics.com
Address: Rubicon Organics Inc.
744 West Hastings Street,
Unit 505,
Vancouver,
British Columbia, V6C 1A5,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX ROMJ Common Shares Canadian National Stock Exchange CA CAD 10. Oct 2018
OTCPK ROMJ.F Common Shares Pink Sheets LLC US USD 10. Oct 2018
Number of employees
Current staff
Staff numbers
0
Rubicon Organics employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:52
End of day share price update: 2019/09/20 00:00
Last earnings filing: 2019/08/26
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.